Monitor the final written decision expected within ~12 months. If the Board cancels claims, it removes potential infringement exposure for AMD; if claims survive, the patent remains enforceable. No near-term stock catalyst.
Price Chart
Executive Summary
The PTAB granted institution of inter partes review in IPR2026-00360, where AMD (petitioner) challenges claims of Fermat International's patent covering analytics and data processing architecture. This is an interlocutory decision — no claims have been cancelled, and a final written decision is expected within about a year. The impact on AMD is minimal at this stage.
PTAB Trial Details
Key Facts
- PTAB instituted IPR2026-00360 on October 19, 2026, at AMD's request.
- The patent at issue is U.S. 12271636, titled 'Analytics, Algorithm Architecture, and Data Processing System and Method,' owned by Fermat International, Inc.
- This is an interlocutory institution decision — no claims have been invalidated.
- AMD is the petitioner; the patent owner is Fermat International, Inc., a non-public entity.
Financial Impact
No financial impact stated in the decision. The patent does not cover a named AMD product or revenue line.
Risk Factors
- A final written decision adverse to AMD could leave the patent intact, preserving any future infringement risk.
- The patent owner may appeal a final adverse decision to the Federal Circuit, extending uncertainty.
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-IPR2026-00360-ins-AMD |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $542.00 | awaiting T+60 | — | $560.23 (+3.36%) |
Oct 22, 2026 4d ago | Institutional Cluster | $516.79 | awaiting T+60 | — | $560.23 (+8.41%) |
Oct 21, 2026 6d ago | PTAB Trial | $507.93 | awaiting T+60 | — | $560.23 (+10.30%) |
Oct 20, 2026 7d ago | PTAB Trial | $552.72 | awaiting T+60 | — | $560.23 (+1.36%) |
Oct 19, 2026 8d ago | PTAB Trial | $534.74 | awaiting T+60 | — | $560.23 (+4.77%) |
Oct 19, 2026 8d ago | PTAB Trial | $534.74 | awaiting T+60 | — | $560.23 (+4.77%) |
Sep 28, 2026 28d ago | Press Release | $607.57 | awaiting T+60 | — | $560.23 (−7.79%) |
Sep 17, 2026 5w ago | Insider Cluster | $559.82 | awaiting T+60 | — | $560.23 (+0.07%) |
Aug 27, 2026 8w ago | Insider Cluster | $465.58 | awaiting T+60 | — | $560.23 (−20.33%) |
Aug 26, 2026 8w ago | Insider Cluster | $476.67 | awaiting T+60 | — | $560.23 (+17.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers